Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals Incorporated ... JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

In case you needed another reason to feel jealous of Chinese car enthusiasts, the Chery Exeed VX C-DM three-row SUV is officially available for pre-order with 610 hp, 1,300 km (over 800 miles ...

2-Year U.S. Treasury Note Continuous Contract $103.535 0.047 0.05% 5-Year U.S. Treasury Note Continuous Contract $108.070 0.148 0.14% 10-Year U.S. Treasury Note Continuous Contract $111.297 0.297 ...

2-Year U.S. Treasury Note Continuous Contract $103.395-0.109-0.11% 5-Year U.S. Treasury Note Continuous Contract $107.539-0.281-0.26% 10-Year U.S. Treasury Note Continuous Contract $110.469-0.406 ...

After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...

Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...